Compare · DASH vs NH
DASH vs NH
Side-by-side comparison of DoorDash Inc. (DASH) and NantHealth Inc. (NH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DASH and NH operate in EDP Services (Technology), so they compete in similar markets.
- DASH is the larger of the two at $35.57B, about 400.1x NH ($88.9M).
- DASH has been more active in the news (27 items in the past 4 weeks vs 1 for NH).
- DASH has more recent analyst coverage (25 ratings vs 0 for NH).
- Company
- DoorDash Inc.
- NantHealth Inc.
- Price
- $194.61-1.10%
- $1.96-32.41%
- Market cap
- $35.57B
- $88.9M
- 1M return
- -10.04%
- -
- 1Y return
- -27.42%
- -
- Industry
- EDP Services
- EDP Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 27
- 1
- Recent ratings
- 25
- 0
DoorDash Inc.
DoorDash, Inc. operates a logistics platform that connects merchants, consumers, and dashers in the United States and internationally. It operates DoorDash marketplace, which provides an array of services that enable merchants to solve mission-critical challenges, such as customer acquisition, delivery, insights and analytics, merchandising, payment processing, and customer support; and offers DoorDash Drive, a white-label logistics service; DoorDash Storefront that enables merchants to offer consumers on-demand access to e-commerce. The company was formerly known as Palo Alto Delivery Inc. and changed its name to DoorDash, Inc. in 2015. DoorDash, Inc. was founded in 2013 and is headquartered in San Francisco, California.
NantHealth Inc.
NantHealth, Inc., together with its subsidiaries, operates as a healthcare IT company in the United States and internationally. It offers Eviti, a software-as-a-service (SaaS) based clinical decision support solution that centralizes clinical content and treatment cost data from Medicare reimbursements and treatment toxicity data; Eviti Connect, which utilizes the platform to offer pre-authorization automation that helps payers and providers navigate the complexities of cancer care; and Eviti Advisor product that allows physicians to access the Eviti platform's comprehensive library of evidence-based treatment standards and protocols to inform treatment decisions. The company also provides NaviNet, a suite of SaaS-based solution enabling payers and providers to streamline communication and consolidate information; NaviNet Open, a payer-provider collaboration platform for communication between health plans and providers; NaviNet AllPayer that provides eligibility, benefit, and claim status information to provider offices for commercial and government plans and CMS for Medicare beneficiaries through the NaviNet portal; and OpenNMS is an open-source network monitoring solution for enterprise-grade networks. In addition, it offers GPS Cancer, a comprehensive molecular profile that integrates whole genome/exome (DNA) sequencing of tumor and normal germline samples and whole transcriptome (RNA) sequencing; Omics Core, an in-vitro diagnostic built on a custom-targeted whole exome sequencing platform; and Quadris, a data solution that includes multi-data analysis, reporting, and professional service. The company was formerly known as Nant Health, LLC and changed its name to NantHealth, Inc. in June 2016. The company was incorporated in 2010 and is headquartered in Culver City, California. NantHealth, Inc. is as a subsidiary of NantWorks, LLC.
Latest DASH
- NHL and DoorDash Announce Multiyear Partnership Across Canada and the United States
- DoorDash and Costco Expand Global Partnership with Nationwide U.S. Launch
- DoorDash and Wonder Announce Strategic Partnership
- CHIEF ACCOUNTING OFFICER Lee Gordon S sold $91,480 worth of shares (413 units at $221.50) as part of a pre-agreed trading plan, decreasing direct ownership by 0.49% to 83,919 units (SEC Form 4)
- Scotiabank initiated coverage on DoorDash with a new price target
- SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Xu Tony
- SKIMS and DoorDash: Solutions For Every Body, Delivered On-Demand
- Director Tang Stanley acquired 30,835 shares as part of a pre-agreed trading plan and sold $6,968,111 worth of shares (30,835 units at $225.98) as part of a pre-agreed trading plan (SEC Form 4)
- CHIEF FINANCIAL OFFICER Inukonda Ravi exercised 1,017 shares at a strike of $7.66 and sold $3,666,784 worth of shares (16,044 units at $228.55) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 217,911 units (SEC Form 4)
- CHIEF EXECUTIVE OFFICER Xu Tony exercised 16,667 shares at a strike of $7.16 and sold $3,833,443 worth of shares (16,667 units at $230.00) as part of a pre-agreed trading plan (SEC Form 4)
Latest NH
- PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
- SEC Form 15-12G filed by NantHealth Inc.
- NantHealth Inc. filed SEC Form 8-K: Leadership Update
- SEC Form EFFECT filed by NantHealth Inc.
- SEC Form EFFECT filed by NantHealth Inc.
- SEC Form POS AM filed by NantHealth Inc.
- SEC Form POS AM filed by NantHealth Inc.
- SEC Form S-8 POS filed by NantHealth Inc.
- SEC Form S-8 POS filed by NantHealth Inc.
- SEC Form S-8 POS filed by NantHealth Inc.